Skip to main content
SpringerLink
Log in

Cardiovascular disease prevention practices by U.S. physicians for patients with diabetes

  • Original Articles
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

OBJECTIVE: Cardiovascular diseases account for the majority of morbidity and mortality in patients with type 2 diabetes mellitus. We describe patterns of cardiovascular disease primary prevention practices used for patients with diabetes by U.S. office-based physicians.

MEASUREMENTS AND MAIN RESULTS: We analyzed a representative sample of 14,038 visits from the 1995 and 1996 National Ambulatory Medical Care Surveys (NAMCS), including 1,489 visits by patients with diabetes. Physicians completed visit forms describing diagnoses, demographics, services provided, and current medications. Diabetes was defined by diagnostic codes; patients with ischemic heart disease or younger than 30 years were excluded. We estimated national visit volumes by extrapolation using NAMCS sampling weights. Independent determinants of prevention practices were evaluated using multiple logistic regression. Actual visits sampled translated into an estimated 407 million office visits in 1995 and 1996, of which 44.8 million (11%) were by patients with diabetes. Overall, patients with diabetes received more cardiovascular disease prevention services than patients without diabetes, including cholesterol reduction (8% vs 5%, P<.001) and exercise counseling (22% vs 13%, P<.001), blood pressure measurement (82% vs 72%, P<.001), and aspirin prescription (5% vs 2%, P<.001). Patients with diabetes and hyperlipidemia were more likely to receive lipid-lowering medications than patients without these diagnoses (67% vs 51%, P=.007), but those who had diabetes and hypertension or who smoked were no more likely than those without to receive antihypertensive medications or smoking cessation counseling, respectively. These effects persisted in multiple logistic regression analyses controlling for potential confounders.

CONCLUSIONS: Patients with diabetes visiting U.S. physicians in 1995 and 1996 received somewhat more cardiovascular disease prevention services than patients without diabetes. Absolute rates of services, however, remained lower than desired based on national recommendations. Current evidence suggests that wider implementation of these recommendations can be expected to reduce the burden of cardiovascular disease in patients with diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care. 1998;21(4):518–24.

    Article  PubMed  CAS  Google Scholar 

  2. Harris MI. Ambulatory medical care for diabetes. In: National Diabetes Data Group, ed. Diabetes in America: Diabetes Data Compiled 1984. Bethesda, Md: National Institutes of Health; 1985. Publication 85-1468.

    Google Scholar 

  3. Harris MI. Testing for blood glucose by office-based physicians in the U.S. Diabetes Care. 1990;13:419–26.

    Article  PubMed  CAS  Google Scholar 

  4. American Diabetes Association. Diabetes 1993 Vital Statistics. Alexandria, Va: American Diabetes Association; 1993.

    Google Scholar 

  5. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS) 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124(1 pt 2):136–45.

    Google Scholar 

  6. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics), II: associated risk factors. Diabetologia. 1990;33:542–8.

    Article  PubMed  CAS  Google Scholar 

  7. Moss SE, Klein R, Klein BEK. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81:1158–62.

    Article  PubMed  CAS  Google Scholar 

  8. Rubin RJ, Altman WM, Mendelson DM. Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab. 1994;78:809A-F.

    Google Scholar 

  9. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care. 1998;21:296–309.

    Article  Google Scholar 

  10. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care. 1997;20:1396–401.

    Article  PubMed  CAS  Google Scholar 

  11. Barrett-Connor E. Does hyperglycemia really cause coronary heart disease? Diabetes Care. 1997;20:1620–3.

    PubMed  CAS  Google Scholar 

  12. Nathan DM, Meigs JB, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is. or is it? Lancet. 1997;350 (suppl 1):4–9.

    Article  Google Scholar 

  13. Knatterud GL, Klimt CR, Levin ME, Jacobsen ME, Goldner MG. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII: mortality and selected non-fatal events with insulin treatment. JAMA. 1978;240:37–42.

    Article  PubMed  CAS  Google Scholar 

  14. Abraira C, Colwell J, Nutall F, et al. Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial: VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med. 1997;157:181–8.

    Article  PubMed  CAS  Google Scholar 

  15. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

    Article  Google Scholar 

  16. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves of diabetic patients with coronary artery disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–20.

    Article  PubMed  CAS  Google Scholar 

  17. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–22.

    Article  PubMed  CAS  Google Scholar 

  18. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.

    Article  Google Scholar 

  19. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998;98:2513–9.

    PubMed  CAS  Google Scholar 

  20. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–8.

    Article  PubMed  CAS  Google Scholar 

  21. The Hypertension Detection and Follow-up Program Cooperative Research Group. Mortality findings for stepped-care and referred-care participants in the Hypertension Detection and Follow-up Program, stratified by other risk factors. Prev Med. 1985;14:312–35.

    Article  Google Scholar 

  22. Curb JD, Pressel SL, Cutler JA, et al., for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA. 1996;276:1886–92.

    Article  PubMed  CAS  Google Scholar 

  23. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.

    Google Scholar 

  24. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–62.

    Article  PubMed  CAS  Google Scholar 

  25. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet. 1999;353:611–6.

    Article  PubMed  CAS  Google Scholar 

  26. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677–84.

    Article  PubMed  CAS  Google Scholar 

  27. Steering Committee of the Physicians’ Health Study Research Group. Final Report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321:129–35.

    Article  Google Scholar 

  28. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:71–2, 81–106.

    Google Scholar 

  29. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care. 1999;22:1887–98.

    Article  PubMed  CAS  Google Scholar 

  30. American Diabetes Association. Consensus statement: Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care. 1989;12:573–9.

    Google Scholar 

  31. American Diabetes Association. Treatment of hypertension in diabetes. Diabetes Care. 1996;19 (suppl 1):S107-S113.

    Google Scholar 

  32. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998;21 (suppl 1):S36-S39.

    Google Scholar 

  33. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care. 1998;21:S45-S46.

    Google Scholar 

  34. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Publication No. 93-3095 ed. Bethesda, MD: National Institutes of Health; 1993.

    Google Scholar 

  35. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–46.

    Article  Google Scholar 

  36. National Center for Health Statistics. Public Use Data Documentation: 1991 National Ambulatory Medical Care Survey. Washington, DC: National Center for Health Statistics, US Public Health Service; 1992.

    Google Scholar 

  37. National Center for Health Statistics. Public Use Data Documentation: 1995 National Ambulatory Medical Care Survey. Washington, DC: National Center for Health Statistics, US Public Health Service; 1996.

    Google Scholar 

  38. National Center for Health Statistics. Public Use Data Documentation: 1996 National Ambulatory Medical Care Survey. Washington, DC: National Center for Health Statistics, US Public Health Service; 1997.

    Google Scholar 

  39. Potthoff R, Woodbury M, Manton K. Equivalent sample size and equivalent degrees of freedom: refinements for inference using survey weights under superpopulation models. J Am Stat Soc. 1992;87:382–96.

    Google Scholar 

  40. DeLozier J. The design and methods of the National Ambulatory Medical Care Survey. Med Group Mgmt. 1974;12:5–7.

    Google Scholar 

  41. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: Wiley and Sons; 1981.

    Google Scholar 

  42. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley-Interscience; 1989.

    Google Scholar 

  43. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121–30.

    Article  PubMed  CAS  Google Scholar 

  44. SAS Institute Inc. SAS/STAT User’ Guide, Version 6. 4th ed. Cary, NC: SAS Institute, Inc; 1989.

    Google Scholar 

  45. National Diabetes Data Group. Diabetes in America. 2nd ed. Bethesda, Md: National Institutes of Health; 1995. NIH publication 95-1468.

    Google Scholar 

  46. Meigs JB, Nathan DM, Wilson PWF, Cupples LA, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: the Framingham Offspring Study. Ann Intern Med. 1998;128:524–33.

    PubMed  CAS  Google Scholar 

  47. American Diabetes Association. Consensus Statement: Detection and Management of Lipid Disorders in Diabetes. Diabetes Care. 1993;16:828–34.

    Google Scholar 

  48. American Diabetes Association. Consensus Statement: Treatment of Hypertension in Diabetes. Diabetes Care. 1993;16:1394–401.

    Google Scholar 

  49. Joint Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154–83.

    Article  Google Scholar 

  50. Stern MP, Patterson JK, Haffner SM, Hazuda HP, Mitchell BD. Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey. JAMA. 1989;262:360–4.

    Article  PubMed  CAS  Google Scholar 

  51. Hiss RG, Anderson RM, Hess GE, Stepien CJ, Davis WK. Community diabetes care: a 10-year perspective. Diabetes Care. 1994;17:1124–34.

    Article  PubMed  CAS  Google Scholar 

  52. Martin TL, Selby JV, Zhang D. Physician and patient prevention practices in NIDDM in a large urban managed-care organization. Diabetes Care. 1995;18:1124–32.

    Article  PubMed  CAS  Google Scholar 

  53. Peters AL, Legorreta AP, Ossorio RC, Davidson MB. Quality of outpatient care provided to diabetic patients: a health maintenance organization experience. Diabetes Care. 1996;19:601–6.

    Article  PubMed  CAS  Google Scholar 

  54. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998;280(7):623–9.

    Article  PubMed  CAS  Google Scholar 

  55. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of diabetes? JAMA. 1990;263:2893–8.

    Article  PubMed  CAS  Google Scholar 

  56. D’Agostino RB Jr, Mykkanen L, Goff DC, et al. Atherosclerosis in type 2 diabetic and non-diabetic subjects with and without previous myocardial infarction: the Insulin Reistance Atherosclerosis Study (IRAS). Circulation 1998;97:817.

    Google Scholar 

  57. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–34.

    Article  PubMed  CAS  Google Scholar 

  58. Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care. 1983;6:285–90.

    Article  PubMed  CAS  Google Scholar 

  59. Malmberg K, Herlitz J, Hjalmarson A, Ryden L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction: retrospective data from two large studies. Eur Heart J. 1989;10:423–8.

    PubMed  CAS  Google Scholar 

  60. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. 1992;13:28–32.

    PubMed  CAS  Google Scholar 

  61. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. β-blockers and sudden cardiac death. Ann Intern Med. 1995;123:358–67.

    PubMed  CAS  Google Scholar 

  62. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol. 1996;77:1273–7.

    Article  PubMed  CAS  Google Scholar 

  63. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577–81.

    PubMed  CAS  Google Scholar 

  64. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118:129–38.

    PubMed  CAS  Google Scholar 

  65. Nielsen FS, Rossing P, Gall M, Skott P, Smidt UM, Parving H. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes. 1997;46:1182–8.

    Article  PubMed  CAS  Google Scholar 

  66. Klein R, Klein BEK, Moss SE. Prevalence of microalbuminuria in older-onset diabetes. Diabetes Care. 1993;16:1325–30.

    Article  PubMed  CAS  Google Scholar 

  67. Morris AD, Boyle DIR, McMahon AD, et al. ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. Diabetes Care. 1997;20:1363–7.

    Article  PubMed  CAS  Google Scholar 

  68. Kaplan NM, Rosenstock J, Raskin P. A differing view of treatment of hypertension in patients with diabetes mellitus. Arch Intern Med. 1987;147:1160–2.

    Article  PubMed  CAS  Google Scholar 

  69. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203–9.

    Article  PubMed  CAS  Google Scholar 

  70. Warram JH, Laffel LMB, Valsania P, Christlieb AR, Krolewski AS. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med. 1991;151:1350–6.

    Article  PubMed  CAS  Google Scholar 

  71. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. Ann Intern Med. 1997;126:955–9.

    PubMed  CAS  Google Scholar 

  72. Lakshman MR, Reda DJ, Materson BJ, Cushman WC, Freis ED. Diuretics and β-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med. 1999;159:551–8.

    Article  PubMed  CAS  Google Scholar 

  73. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645–52.

    Article  PubMed  CAS  Google Scholar 

  74. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlopidine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597–603.

    Article  PubMed  CAS  Google Scholar 

  75. Cutler J. Which drug for treatment of hypertension? Lancet. 1999;353:604–5.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Received from the General Medicine Division, Massachusetts General Hospital, Medical Services, Boston, Mass

    James B. Meigs MD, MPH & Randall S. Stafford MD, PhD

  2. Department of Medicine, Harvard Medical School, Boston, Mass

    James B. Meigs MD, MPH & Randall S. Stafford MD, PhD

Authors
  1. James B. Meigs MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Randall S. Stafford MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James B. Meigs MD, MPH.

Additional information

This study was supported by an American Diabetes Association Clinical Research Grant (JBM) and a Mentored Clinical Scientist Development Award from the National Heart, Lung and Blood Institute (K08-HL03548, RSS). Assistance with statistical analyses was provided by Bismruta Misra, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meigs, J.B., Stafford, R.S. Cardiovascular disease prevention practices by U.S. physicians for patients with diabetes. J GEN INTERN MED 15, 220–228 (2000). https://doi.org/10.1111/j.1525-1497.2000.03079.x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1111/j.1525-1497.2000.03079.x

Key words

Search

Navigation